MedTrace Logo

Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT.

NCT06837987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-09-22

No results posted yet for this study

Summary

The investigators retrospectively evaluted the safety and efficacy of the modified transplantation conditioning and aGVHD prophylaxis in severe aplastic anemia in 4 transplantation centers.

Conditions

  • Aplastic Anaemia
  • Transplantation Conditioning

Interventions

OTHER

Modified transplantation system

Modified transplantation conditioning include: Fludarabine 30mg/m2\*6 day, Melphalan 100mg/m2\*1 day, cyclophosphamide 50mg/kg\*2 day.

Sponsors & Collaborators

  • Hematology department of the 920th hospital

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-06-30
Completion
2025-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837987 on ClinicalTrials.gov